#17USNASDAQMid-cap

HALO

Halozyme

$110.76USD

Data as of 2026-09-05

Composite Score70.6Exceptional

≤−99

Margin of safety−99%Expensive

Fair value$55.64

Target$132.81

Loss chance51%Neutral

SizeLarge cap

SectorHealth Care

Dividend—

TypeCommon stock

Price

Pillar breakdown

0–100 percentile rank against the current universe (sector-relative for Quality / Value / Growth / Profitability)

Health Care median (n=163)

Quality
Profit margins & asset efficiency
93
Exceptional
Health Care median (n=163) 51
Value
Price vs fundamentals
30
Weak
Health Care median (n=163) 51
Growth
Revenue & earnings trajectory
90
Exceptional
Health Care median (n=163) 50
Momentum
Recent price strength
73
Exceptional
Health Care median (n=163) 62
Health
Balance sheet & solvency
65
Strong
Health Care median (n=163) 56
Profitability
ROE, ROA, ROIC
85
Exceptional
Health Care median (n=163) 49
Technical
Trend & volatility signals
71
Exceptional
Health Care median (n=163) 62
Risk
Volatility & drawdown profile
68
Strong
Health Care median (n=163) 47

025405570100

Exceptional (70+)Strong (55–70)Average (40–55)Weak (25–40)Poor (<25)

Pillars not shown: Sentiment, ML (Phase 5+).

Fair price check

4 different valuation methods each estimate what HALO should be worth, then we compare to today's price.

Looks overvalued

Models suggest HALO is trading above fair value

Today's price

$110.76

Median fair price

$55.64

-50% vs today's price

Of 3 methods:1 say fair2 say pricey(1 outlier excluded)

EV/EBITDAFair
thinks it's fairly priced — estimates $132.81, about 20% above today
P/E multiplesOvervalued
thinks it's expensive — estimates $88.04, about 21% below today
DCF (2-stage)Overvalued
thinks it's expensive — estimates $23.23, about 79% below today
P/B multiplesOutlier
estimate looks unreliable — estimates $6.87 — likely unreliable

How to read this: “Cheap” = method's fair price is at least 20% above today. “Fair” = within ±10–20%. “Pricey” = at least 10% below today. Outliers (values more than 5× or less than 0.2× today's price) are excluded.

Fair price ensemble

Median fair: $55.64
Margin of safety(vs fair value): < −99%
Max (ex-outliers): $132.81
Tangible BVPS: —

Extreme P/B estimate

Median of all applicable methods (current price $110.76). Per-method estimates + each method’s cheap/fair/pricey read are in the Fair price check above. Outliers above 5× or below 0.2× current price are excluded from the max but kept in the median. See methodology for the 6-method ensemble + 7 defenses.

Defense layer. Flags mark elevated risk, never confirmed fraud. This model cannot catch every manipulation and decays after publication — weigh it against its stated error rates.

Supporting dataRaw fundamentals & data-quality provenance behind the scores above

Raw fundamentals (SEC EDGAR)

Metric	Value
Market cap	$12.57B
Revenue (TTM)	$1.66B
Net income (TTM)	$413.60M
Operating cash flow (TTM)	$818.60M
CapEx (TTM)	$12.37M
Free cash flow (TTM)CFO − CapEx	$806.22M
Total assets	$2.58B
Total liabilities	$2.43B
Stockholders' equity	$143.54M
Cash & equivalents	$163.14M
Shares outstanding	113.50M
EPS (basic)	$3.64
EPS (diluted)	$3.64
P/E ratio (TTM)	30.39

TTM = trailing twelve months. Balance sheet items are point-in-time (latest filing).

Data quality

Latest filed date: 2026-08-06
Latest period end: 2026-07-31
Filing lag: 30 days
Missing metrics: 2(gross_profit, dividends_paid)